Abreos Biosciences Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 6
Employees
  • Latest Deal Type
  • M&A

Abreos Biosciences General Information

Description

Developer of peptide antigen mimetics technology designed to improve the development and commercialization of biopharmaceuticals. The company's platform are laboratory-based and point-of-care assays that enable precision dosing and counterfeit detection of biologic drugs as well as permits for direct monitoring of blood concentrations of monoclonal antibody drugs for dosage, enabling health care industry to get customizable assay to improve outcome.

Contact Information

Website
www.abreos.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Parent Company
AegirBio
Primary Office
  • 2223 Avenida de la Playa
  • Suite 206
  • La Jolla, CA 92037
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Abreos Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 25-Jan-2021 00.000 Completed Generating Revenue
7. Seed Round 15-Sep-2020 00.000 00.000 Completed Generating Revenue
6. Grant 25-Feb-2020 00.000 00.000 Completed Generating Revenue
5. Seed Round 29-Mar-2016 000 Cancelled Generating Revenue
4. Seed Round 28-Jun-2016 00.000 00.000 Completed Generating Revenue
3. Grant 25-Sep-2015 00.000 Completed Generating Revenue
2. Grant 23-Sep-2014 $371K Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2014 Completed Generating Revenue
To view Abreos Biosciences’s complete valuation and funding history, request access »

Abreos Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of peptide antigen mimetics technology designed to improve the development and commercialization of biopharmac
Biotechnology
La Jolla, CA
6 As of 2020
00.000
000000&0 00.000

0000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 00000000
San Francisco, CA
0 As of 0000
000 0000-00-00
000000&0

00000 00

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000000000000
San Diego, CA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Abreos Biosciences Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Trianni Formerly Accelerator/Incubator backed San Francisco, CA 0 000000&0
00000 0000000 0000 Formerly VC-backed San Diego, CA 00 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000
00000000000 Private Debt Financed Rosemont, IL 000 000000000 -
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
You’re viewing 5 of 15 competitors. Get the full list »

Abreos Biosciences Patents

  • 9

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Abreos Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180291059-A1 Immunoaffinity purification of antibodies using mimetopes Abandoned 04-Apr-2017 00000000
EP-3606937-A4 Immunoaffinity purification of antibodies using mimetopes Withdrawn 04-Apr-2017 00000000
EP-3606937-A1 Immunoaffinity purification of antibodies using mimetopes Withdrawn 04-Apr-2017 00000000
EP-3497444-A4 Detection and quantification of natalizumab Pending 12-Aug-2016 00000000000 0
EP-3497444-A1 Detection and quantification of natalizumab Pending 12-Aug-2016 G01N33/6854
To view Abreos Biosciences’s complete patent history, request access »

Abreos Biosciences Executive Team (8)

Name Title Board Seat Contact Info
Bradley Messmer Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Reed McCalmon Director of Finance
Michael Williams Board Advisor
You’re viewing 3 of 8 executive team members. Get the full list »

Abreos Biosciences Board Members (3)

Name Representing Role Since
Bradley Messmer Ph.D Abreos Biosciences Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Neil Senturia Blackbird Ventures (La Jolla) Executive Chairman & Advisor 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Abreos Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abreos Biosciences Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blackbird Ventures (La Jolla) Venture Capital Minority 000 0000 000000 0
CONNECT (Accelerator) Accelerator/Incubator Minority 000 0000 000000 0
Keshif Ventures Angel Group Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
TLP Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Abreos Biosciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 27-Nov-2019 00000 0000 Monitoring Equipment
To view Abreos Biosciences’s complete investments history, request access »

Ready to get started?

Request a free trial